A curated overview of published scientific literature on the compounds we supply. All information is for educational purposes. VialX makes no therapeutic claims.
Retatrutide (LY3437943) is a synthetic peptide that simultaneously targets three G-protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GcgR).
The triple-agonist pharmacological profile differentiates retatrutide from single-agonist GLP-1 analogues and dual GLP-1/GIP agonists, representing a distinct research tool for exploring incretin axis biology and metabolic pathway cross-talk in cell and animal models.
Phase 2 study published data demonstrating the receptor pharmacodynamics of retatrutide. Preclinical data highlighted the tri-agonist binding kinetics and downstream signaling through Gs-coupled pathways in adipocyte and hepatocyte cell lines. Researchers noted significant dose-dependent cAMP accumulation at all three receptor targets. (Summarized for research context — not a therapeutic claim.)
In vitro and rodent model investigations of triple incretin axis activation. Studies characterized the relative potency ratios at GLP-1R, GIPR, and GcgR in cell-based assays, showing that simultaneous agonism at all three receptors produced additive downstream effects on cAMP signaling and lipid metabolism pathways compared to single- or dual-agonist controls.
SAR analysis investigating the effect of amino acid substitutions and fatty acid chain modifications on triple agonist binding affinity and receptor selectivity. Key findings included the importance of the GLP-1(7-37) backbone for GLP-1R affinity and the role of the C18 fatty diacid moiety in extending plasma half-life through albumin binding.
In vitro research in 3T3-L1 adipocyte models examined the effects of GcgR co-activation on intracellular lipolytic signaling. Results indicated that the addition of glucagon receptor agonism to GLP-1/GIP dual agonism produced augmented effects on HSL phosphorylation and fatty acid release in the cell model, representing a distinct pharmacological mechanism for in vitro research.
Hepatocyte cell culture studies examining the effects of glucagon receptor agonism on glycogenolysis and gluconeogenesis signaling pathways. The addition of GcgR activity to GLP-1R stimulation in co-culture experiments revealed complex interplay in glucose transporter expression and hepatic glucose output regulation.
Reproducible research requires reliable, high-purity reagents. VialX provides full COA documentation to support your lab's quality assurance requirements.
Empty cart.